GlassScriptPhysician profile
Hazem Malas
NPI 1295022424
$49,965.29
in general payments reported to CMS, 2019-2025
19 companies · $12K in 2025
The $12K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,610 · 2020: $6,317 · 2021: $5,287 · 2022: $8,266 · 2023: $4,183 · 2024: $11K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Travel and Lodging: $1,972 · Food and Beverage: $1,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,000.00 |
| Travel and Lodging | $1,971.63 |
| Food and Beverage | $1,512.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $32,413.84 | 2019-2025 | Watchman Access System, Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $6,352.28 | 2019-2022 | |
| Amarin Pharma, INC. | $6,222.44 | 2019-2020 | |
| Abbott Laboratories | $2,946.37 | 2019-2025 | Triclip |
| Edwards Lifesciences Corporation | $1,374.47 | 2022-2024 | Evoque |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $159.86 | 2019-2024 | Lifevest |
| Medtronic, INC. | $102.37 | 2025 | Corevalve Evolut R |
| Novo Nordisk INC | $92.28 | 2020 | |
| Canon Medical Systems USA, INC. | $67.51 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $56.74 | 2024 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.97 | 2019-2020 | |
| Amgen INC. | $26.49 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.71 | 2019 | |
| Kestra Medical Technology Services, INC. | $24.98 | 2023 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $18.13 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $15.93 | 2019 | |
| Portola Pharmaceuticals, LLC | $13.50 | 2019 | |
| Allergan, INC. | $13.42 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hazem Malas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.